JP7474269B2 - がんを治療するための組成物及び方法 - Google Patents

がんを治療するための組成物及び方法 Download PDF

Info

Publication number
JP7474269B2
JP7474269B2 JP2021555445A JP2021555445A JP7474269B2 JP 7474269 B2 JP7474269 B2 JP 7474269B2 JP 2021555445 A JP2021555445 A JP 2021555445A JP 2021555445 A JP2021555445 A JP 2021555445A JP 7474269 B2 JP7474269 B2 JP 7474269B2
Authority
JP
Japan
Prior art keywords
compound
nmr
erlotinib
egfr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526266A5 (https=
JP2022526266A (ja
Inventor
エー． ネイサンソン，デイヴィッド
イー． ジュング，マイケル
ツァン，ジョナサン
アーナー，ロレンズ
エム． クラーク，ピーター
エフ． クロウゲシー，ティモシー
キム，ギュドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022526266A publication Critical patent/JP2022526266A/ja
Publication of JP2022526266A5 publication Critical patent/JP2022526266A5/ja
Priority to JP2024064400A priority Critical patent/JP7789832B2/ja
Application granted granted Critical
Publication of JP7474269B2 publication Critical patent/JP7474269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021555445A 2019-03-15 2020-03-13 がんを治療するための組成物及び方法 Active JP7474269B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024064400A JP7789832B2 (ja) 2019-03-15 2024-04-12 がんを治療するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962819322P 2019-03-15 2019-03-15
US62/819,322 2019-03-15
US201962904241P 2019-09-23 2019-09-23
US62/904,241 2019-09-23
PCT/US2020/022743 WO2020190765A2 (en) 2019-03-15 2020-03-13 Compositions and methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024064400A Division JP7789832B2 (ja) 2019-03-15 2024-04-12 がんを治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022526266A JP2022526266A (ja) 2022-05-24
JP2022526266A5 JP2022526266A5 (https=) 2023-03-20
JP7474269B2 true JP7474269B2 (ja) 2024-04-24

Family

ID=72521289

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555445A Active JP7474269B2 (ja) 2019-03-15 2020-03-13 がんを治療するための組成物及び方法
JP2024064400A Active JP7789832B2 (ja) 2019-03-15 2024-04-12 がんを治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024064400A Active JP7789832B2 (ja) 2019-03-15 2024-04-12 がんを治療するための組成物及び方法

Country Status (17)

Country Link
US (3) US11377451B2 (https=)
EP (1) EP3938354A4 (https=)
JP (2) JP7474269B2 (https=)
KR (1) KR102809395B1 (https=)
CN (2) CN115215808B (https=)
AU (1) AU2020241703B2 (https=)
BR (1) BR112021018295A2 (https=)
CA (1) CA3133688A1 (https=)
CL (1) CL2021002409A1 (https=)
CO (1) CO2021013496A2 (https=)
CR (1) CR20210498A (https=)
IL (1) IL286350A (https=)
MX (1) MX2021011272A (https=)
PH (1) PH12021552208A1 (https=)
SA (1) SA521430328B1 (https=)
SG (1) SG11202109662YA (https=)
WO (1) WO2020190765A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR102809395B1 (ko) 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022061201A1 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
US20240165132A1 (en) * 2021-05-12 2024-05-23 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
EP4405360A4 (en) * 2021-09-23 2025-08-20 Erasca Inc POLYMORPHIC FORMS OF EGFR INHIBITOR
WO2023244639A1 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors
WO2024081447A1 (en) * 2022-10-14 2024-04-18 The Regents Of The University Of California Egfr inhibitors for treating lung cancer
WO2024102177A1 (en) * 2022-11-08 2024-05-16 The Regents Of The University Of California Combination therapies for the treatment of brain cancer
WO2025117739A1 (en) * 2023-11-27 2025-06-05 Erasca, Inc. Compositions and methods for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061202A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061201A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CN1854130B (zh) 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
WO2008046242A1 (fr) 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
ITPD20110091A1 (it) 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
NZ732511A (en) * 2014-12-15 2018-11-30 Univ Michigan Regents Small molecule inhibitors of egfr and pi3k
CA2974442A1 (en) * 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
CN105017163A (zh) 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
US10473255B2 (en) 2015-12-29 2019-11-12 Ge-Hitachi Nuclear Energy Americas Llc Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
CN106432202B (zh) 2016-09-22 2019-04-02 郑州大学第一附属医院 喹唑啉类衍生物及其应用
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR102809395B1 (ko) 2019-03-15 2025-05-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 암을 치료하기 위한 조성물 및 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061202A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061201A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions and methods for treating cancer
WO2022061299A1 (en) 2020-09-21 2022-03-24 The Regents Of The University Of California Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
WO2023244639A1 (en) 2022-06-14 2023-12-21 The Regents Of The University Of California Methods of predicting cns cancer response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
CA3133688A1 (en) 2020-09-24
CL2021002409A1 (es) 2022-06-17
CN115215808A (zh) 2022-10-21
EP3938354A2 (en) 2022-01-19
SG11202109662YA (en) 2021-10-28
AU2020241703A1 (en) 2021-10-14
US20220064177A1 (en) 2022-03-03
CO2021013496A2 (es) 2022-01-17
SA521430328B1 (ar) 2024-03-28
PH12021552208A1 (en) 2022-05-30
WO2020190765A3 (en) 2020-11-26
JP7789832B2 (ja) 2025-12-22
CN115215808B (zh) 2025-04-18
JP2024102094A (ja) 2024-07-30
AU2020241703B2 (en) 2026-02-05
US11377451B2 (en) 2022-07-05
IL286350A (en) 2021-10-31
KR20210151820A (ko) 2021-12-14
JP2022526266A (ja) 2022-05-24
WO2020190765A2 (en) 2020-09-24
KR102809395B1 (ko) 2025-05-16
CR20210498A (es) 2022-01-11
US20250145634A1 (en) 2025-05-08
US20230115366A1 (en) 2023-04-13
EP3938354A4 (en) 2022-12-28
CN113811528A (zh) 2021-12-17
BR112021018295A2 (pt) 2021-11-23
MX2021011272A (es) 2021-10-01

Similar Documents

Publication Publication Date Title
JP7474269B2 (ja) がんを治療するための組成物及び方法
JP2023159152A (ja) がんを治療するための組成物及び方法
JP6154404B2 (ja) オキサゾリジン−２−オン化合物およびｐｉ３ｋ阻害剤としてのその使用
TW202140485A (zh) 化合物及其用途
Dokla et al. 1, 2, 4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
JP2019508404A (ja) 癌患者の層別化および癌治療のための化合物、組成物および方法
US20230364091A1 (en) Compositions and methods for treating cancer
HK40083017A (en) Compositions and methods for treating cancer
HK40062377A (en) Compositions and methods for treating cancer
EA044668B1 (ru) Композиции и способы для лечения рака
HK40037064A (en) Compositions and methods for treating cancer
TW202523325A (zh) 新穎化合物、包含其的醫藥組成物及使用其治療癌症的方法
CN120379671A (zh) 用于治疗癌症的化合物
EP4724150A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240412

R150 Certificate of patent or registration of utility model

Ref document number: 7474269

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150